CAP における敗血症の進行を防ぐためのクラリスロマイシン治療 (REACT) (REACT)
市中肺炎における敗血症の進行を防ぐためのバイオマーカーに基づく早期エラリスロマイシン治療: React ランダム化臨床試験
The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early start of adjunctive oral clarithromycin guided by suPAR to prevent the progression into sepsis in patients with community-acquired pneumonia (CAP) at risk. This can be achieved by endpoints incorporating clinical benefit with the effect of treatment on the improvement of the immune dysregulation of CAP. The secondary objectives of REACT are to investigate the impact of early adjunctive treatment with clarithromycin on the resolution of CAP at the test-of-cure (TOC) visit.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Sepsis is recognized nowadays as one of the major causes of global morbidity and mortality. One analysis of global data revealed that 49 million of new cases are admitted to hospitals every year and that 11 million of the patients die. Sepsis is the life-threatening organ dysfunction which develops due to the dysregulated response of the host to an infection; mortality is ranging between 20 and 25%. The most common infections leading to sepsis are infections of the lower respiratory tract (LRTIs) mainly community-acquired pneumonia (CAP).
Numerous attempts have been done the last decades to decrease the substantial mortality of sepsis. Standard-of-care (SoC) therapy for sepsis is framed by the Surviving Sepsis Campaign (SSC) guidelines which are published every four years since 2004 (last publication 2021). The backbone of these guidelines is the early administration of intravenous antibiotics and fluids. In all editions of the SSC guidelines "early" means less than one hour from sepsis recognition. The experts recognize that the secret to decrease mortality is to intervene early before the dysregulated host response to the infection becomes exaggerated and impossible to withhold. The experts state that for every hour of delay in intervention the odds for survival decrease by relative 7.6%. Then the real ambiguity moves on how the initiation of the sepsis process can be recognized earlier than clinical deterioration appears.
The only way to achieve our current strategy is to implement a strategy linking the increase of a biomarker to an early intervention. This biomarker can be either a measured circulating protein or a bioscore. An example of how this strategy works is the biomarker-guided treatment of early COVID-19 (coronavirus disease 2019) recently approved by the European Medicines Agency (EMA). The biomarker suPAR (soluble urokinase plasminogen activator receptor) was used as a tool to recognize the patient at risk for severe respiratory failure and guided the start of the drug anakinra. This led to an overall 64% clinical benefit so as to become the first early precision intervention approved for infections by the EMA. The registered cut-off of suPAR which guides early intervention is 6 ng/ml or more.
The suPAR assay is not commercially available in the United States. However, all enrolled patients in SAVE-MORE trial were required to have a plasma soluble urokinase plasminogen activator receptor (suPAR) level ≥ 6 ng/mL. SAVE-MORE was double-blind, randomized controlled trial evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure as identified by plasma suPAR ≥6 ng ml-1, 85.9% (n = 510) of whom were receiving dexamethasone. In order to identify a comparable population as was studied in the SAVE-MORE trial, an alternative patient identification method was developed by the Food and Drug Administration (FDA) of the United States to select patients most likely to have suPAR ≥ 6 ng/mL based on commonly measured patient characteristics (Appendix I). This score contains eight clinical variable and patients meeting at least 3 of the variables should receive early anakinra treatment. Patients meeting at least three of the following eight criteria are considered likely to have suPAR ≥ 6 ng/mL at baseline: i) age 75 years or more; ii) need for oxygen supplementation; iii) current/previous smoking status; iv) Sequential Organ Failure Assessment (SOFA) score 3 or more; v) neutrophil-to-lymphocyte ratio (NLR) 7 or more; vi) blood hemoglobin 10.5 g/dL or less; vii) medical history of ischemic stroke; and viii) blood urea 50 mg/dL or more and/or medical history of renal disease. According to the SmPC, suPAR is a biomarker is used at the Emergency Department (ED) for the triage of patients for early discharge home or not; levels exceeding 6ng/ml advise for hosptialization.
With this precision-embedded approach adjunctive treatments may attenuate the exaggerated response of the host and improve outcomes. Macrolides are a unique class of drugs that combine both antibiotic and anti-inflammatory properties. Several meta-analyses have proven that addition of a macrolide to treatment decreases mortality by community-acquired pneumonia (CAP). However, the mortality benefit from macrolides treatment is coming from meta-analyses and no randomized clinical trial (RCT) has been published so far to demonstrate such a benefit. This is also heavily criticized in the recently published guidelines by the European Society of Intensive Care with the European Society of Clinical Microbiology and Infections Diseases (ESCMID) for the management of severe CAP where the recommendation for the co-administration of macrolides to β-lactams is characterized as low-quality evidence.
The only available RCT testing the value of early intervention with macrolides in patients with community-acquired pneumonia (CAP) is ACCESS (A randomized clinical trial of oral Clarithromycin in Community-acquired pneumonia to attenuatE inflammatory responseS and improve outcomeS) (EudraCT number 2020-004452-15; ClinicalTrials.gov NCT04724044). The inclusion criteria of the ACCESS trial have the characteristics of precision therapy i.e. participants were adults with CAP, meeting at least two of the criteria of the systemic inflammatory response syndrome, with SOFA (sequential organ failure assessment) score 2 or more and circulating procalcitonin 0.25 ng/ml or more. ACCESS had a composite primary endpoint pointing towards an early anti-inflammatory clinical benefit of clarithromycin. Patients achieving the endpoint should meet both two conditions A and B by day 4 since start of the study drug: condition A defined as at least 50% decrease of the respiratory symptoms score (RSS); and condition B defined as at least 30% decrease of the baseline SOFA score and/or favorable PCT kinetics (defined as at least 80% decrease of the baseline PCT or PCT less than 0.25 ng/ml). The study succeeded in the primary endpoint since this was met in 38.3% of patients randomized to the SoC + placebo group and in 67.9% of patients randomized to the SoC + clarithromycin group (p<0.0001). The ACCESS study also showed remarkable efficacy in all secondary endpoints and mainly to those endpoints pointing towards prevention of sepsis progression:
11.30% of patients treated with SoC and placebo progressed into sepsis during the 28-day follow-up compared to only 2.25% of patients treated with oral clarithromycin and placebo (hazard ratio 0.19; p: 0.009) 27.8% of patients treated with SoC and placebo developed a new sepsis episode during the 28-day follow-up compared to only 14.8% of patients treated with oral clarithromycin and placebo (hazard ratio 0.48; p: 0.009); and 65.4% of patients treated with SoC and placebo were discharged from hospital alive compared to 78.4% of patients treated with oral clarithromycin and placebo (hazard ratio 1.38; p: 0.027) Post-hoc analysis showed that 87.4% of study participants were meeting at least 3 of the FDA clinical score making the participants at high likelihood for suPAR 6 ng/ml or more. This means that use of suPAR can discriminate early patients with CAP who are at high likelihood to receive benefit towards prevention of progression into sepsis and organ dysfunction through early start of clarithromycin treatment.
Data from the ACCESS study also showed a significant effect of clarithromycin treatment on modulation of immune dysregulation taking place in CAP by day 4 when the primary endpoint was met. These data points towards improvement of the function of circulating monocytes towards better production of TNFα (tumour necrosis factor-alpha) after stimulation, decrease of circulating interleukin (IL)-10 and improvement of the IL-8/IL-10 ratio.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Athens、ギリシャ、11521
- 1st Department of Internal Medicine, Athens Naval Hospital
-
Athens、ギリシャ、11527
- 2nd Pulmonary Department, SOTIRIA Chest Diseases Athens General Hospital
-
Thessaloniki、ギリシャ、54642
- 2nd Propaedeutic Department of Internal Medicine, IPPOKRATEIO, Thessaloniki General Hospital
-
-
Athens
-
Athens、Athens、ギリシャ、115 27
- 5th Pulmonary Department, SOTIRIA Athens General Hospital of Chest Diseases
-
-
Greece
-
Athens、Greece、ギリシャ
- 1st Department of Internal Medicine - General Hospital of Athens "Sismanogleio-Amalia Fleming"
-
Athens、Greece、ギリシャ
- 1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki
-
Athens、Greece、ギリシャ
- 1st Department of Internal Medicine, EVANGELISMOS Athens General Hospital
-
Athens、Greece、ギリシャ
- 1st Department of Internal Medicine, G. GENNIMATAS Athens General Hospital
-
Athens、Greece、ギリシャ
- 1st Department of Internal Medicine, General University Hospital of Ioannina
-
Athens、Greece、ギリシャ
- 1st Department of Internal Medicine, KORGIALENEIO-BENAKEIO E.E.S. Athens General Hospital
-
Athens、Greece、ギリシャ
- 1st Department of Internal Medicine, THRIASIO General Hospital of Elefsis
-
Athens、Greece、ギリシャ
- 1st University Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens
-
Athens、Greece、ギリシャ
- 2nd Department of Internal Medicine, General Hospital of Eleusina Thriasio
-
Athens、Greece、ギリシャ
- 2nd Department of Internal Medicine, TZANEIO Piraeus General Hospital
-
Athens、Greece、ギリシャ
- 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis
-
Athens、Greece、ギリシャ
- 2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital
-
Athens、Greece、ギリシャ
- 3rd Department of Internal Medicine - General State Hospital of Nikaia "Saint Panteleimon" - West Attica General Hospital
-
Athens、Greece、ギリシャ
- 3rd Department of Internal Medicine, General Hospital of Athens KORGIALENEIO- BENAKEIO E.E.S.
-
Athens、Greece、ギリシャ
- 3rd University Department of Internal Medicine, SOTIRIA Athens General Hospital of Chest Diseases
-
Athens、Greece、ギリシャ
- 4th Department of Internal Medicine, Attikon University Hospital
-
Athens、Greece、ギリシャ
- 6th Pulmonary Medicine Department, SOTIRIA General Hospital of Chest Diseases of Athens
-
Athens、Greece、ギリシャ
- Department of Chest Medicine, EVANGELISMOS Athens General Hospital
-
Athens、Greece、ギリシャ
- Department of Internal Medicine, Larissa University General Hospital
-
Athens、Greece、ギリシャ
- Department of Internal Medicine, Patras University General Hospital
-
Athens、Greece、ギリシャ
- Department of Pulmonary Medicine, General Hospital of Kerkira
-
Athens、Greece、ギリシャ
- Emergency Department, TZANEIO Piraeus General Hospital
-
-
Marousi
-
Athens、Marousi、ギリシャ、15126
- 2nd Department of Internal Medicine, Simsanogleio General Hospital
-
-
Syros
-
Ermoupoli、Syros、ギリシャ、841 00
- Department of Internal Medicine, General Hospital of Syros
-
-
Thessaloniki
-
Thessaloniki、Thessaloniki、ギリシャ、564 29
- 3rd Department of Internal Medicine, PAPAGEORGIOU General Hospital of Thessaloniki
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age equal to or above 18 years
- Male or female gender
- In case of women of reproductive age, willingness to use dual contraceptive method during the study period
- Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation
- Community-acquired pneumonia (CAP)
- Presence of at least two of the following signs: i) cough; ii) purulent sputum expectoration; iii) dyspnea; and/or iv) pleuritic chest pain
- PCT ≥0.25 ng/ml
- suPAR ≥6 ng/ml
Exclusion Criteria:
- Age below 18 years
- Denial of written informed consent
- Any stage IV malignancy
- Any do not resuscitate decision
- Patients necessitating non-invasive ventilation or mechanical ventilation
- Hospitalization in Intensive Care Unit
- Infection by SARS-CoV-2
- Oral or IV intake of corticosteroids at a daily dose equal to or greater than 0.4 mg/kg prednisone for a period greater than the last 15 days
- Intake of any macrolide for the current episode of CAP under study
- Known infection by the human immunodeficiency virus
- Any chronic anti-cytokine treatment for more than two months
- QTc interval at rest in the ECG ≥500 msec or history of know long QT syndrome
- Medical history of allergy to macrolides
- Concomitant oral intake of astemizole, cizapride, doperidone, pimozide, terfenadine, midazolam, ranolazine, ergot alkaloids (e.g. ergotamine and dihydroergotamine), lomitapide and colchicine; patients may be enrolled in the trial if they stop these drugs during trial participation.
- Medical history of torsades de pointes arrhythmia
- Concomitant intake of lovostatin or simvastatin; patients may be enrolled in the trial if they stop these drugs during trial participation.
- Concomitant presence of end-stage liver failure and end-stage renal failure.
- Severe hypokalemia or severe hypomagnesemia; a patient may be enrolled one any of these electrolyte disturbances are restored.
- Any contradictions for macrolide uptake
- Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study
- Participation in any other interventional trial within the last 30 days
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo
These patients will be treated with 1 placebo tablet every 12 hours and it is suggested that all patients receive at least one of antibiotics based on the current ESCMID guidelines for severe CAP13 (Ampicillin/sulbactam, Amoxicillin/clavulanate, Piperacillin/tazobactam, Ceftriaxone, Cefotaxime, Ceftaroline, Moxifloxacin). The total duration of treatment will be seven days.Τhe dosage, the dosage regime, the route and mode of administration, and the treatment period for the aforementioned antibiotics can be found in the relevant SmPCs (available in References). However, the attending physician may modify the antimicrobial treatment based on risk factors for multidrug-resistance pathogens, microbiology results and local epidemiology. All SoC treatment products and clarithromycin are authorised for use in Greece, where the trial will be conducted. |
Oral tablets of similar appearance to active study drug
他の名前:
|
|
アクティブコンパレータ:Clarithromycin
These patients will be treated with oral clarithromycin 500 mg twice daily for seven days and it is suggested that all patients receive at least one of antibiotics based on the current ESCMID guidelines for severe CAP13 (Ampicillin/sulbactam, Amoxicillin/clavulanate, Piperacillin/tazobactam, Ceftriaxone, Cefotaxime, Ceftaroline, Moxifloxacin). The total duration of treatment will be seven days.Τhe dosage, the dosage regime, the route and mode of administration, and the treatment period for the aforementioned antibiotics can be found in the relevant SmPCs (available in References). However, the attending physician may modify the antimicrobial treatment based on risk factors for multidrug-resistance pathogens, microbiology results and local epidemiology. All SoC treatment products and clarithromycin are authorised for use in Greece, where the trial will be conducted. |
Oral tablets of 500mg of clarithromycin
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change of baseline respiratory symptoms score
時間枠:4 Days
|
At least 50 percent (%) decrease of the sum of scoring (0-12) for the symptoms of cough (0-3), dyspnea (0-3), purulent sputum expectoration (0-3) and pleuritic chest pain (0-3) between baseline and Study Day 4 |
4 Days
|
|
Change of baseline total sequential organ failure assessment (SOFA) score
時間枠:4 Days
|
At least 30 percent (%) decrease between baseline sequential organ failure assessment (SOFA) score and measured sequential organ failure assessment (SOFA) score at Study Day 4. |
4 Days
|
|
Change of baseline on both plasma PCT and plasma IL-10 or IL-8 to IL-10 ratio
時間枠:4 Days
|
Plasma PCT on visit 4 has decreased by at least 80% from baseline PCT on screening or it is below 0.25 ng/ml AND ([plasma IL-10 on visit 4 has decreased by at least 25% from IL-10 of visit 1 or it is below the lower limit of detection] OR [the IL-8 to IL-10 ratio of day 4 has decreased less than 15% from the IL-8 to IL-10 ratio of visit 1]). |
4 Days
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The number of patients that succeeded the resolution of CAP at the test of cure (TOC) visit.
時間枠:14 Days
|
This is also analyzed separately for patients infected or colonized by clarithromycin-susceptible and clarithromycin-resistant S.pneumoniae and it is defined as the complete resolution of RSS |
14 Days
|
|
Need for up-escalation of the SoC administered antibiotics.
時間枠:28 Days
|
This is considered as the change of the baseline administered SoC antibiotics into more broad-spectrum antibiotics. |
28 Days
|
|
Survival
時間枠:28 Days
|
Alive hospital discharge until day 28 |
28 Days
|
|
Change of baseline sequential organ failure assessment (SOFA) score
時間枠:8 Days
|
Achievement of more than 50% decrease of baseline SOFA score at end-of-treatment (EOT) visit |
8 Days
|
|
Change of baseline on both plasma PCT and plasma IL-10 or IL-8 to IL-10 ratio
時間枠:8 Days
|
Score of improvement of CAP-associated immune dysregulation (see sections of Laboratory procedures) at the end-of-treatment (EOT) visit |
8 Days
|
|
Cytokine production
時間枠:4 Days
|
Change of cytokine production by PBMCs on day 4 from visit 1 |
4 Days
|
|
28-Day Mortality
時間枠:28 Days
|
Association of 28-day mortality with the score of improvement of CAP-associated immune dysregulation |
28 Days
|
|
90-Day Mortality
時間枠:90 Days
|
Association of 90-day mortality with score of improvement of CAP-associated immune dysregulation |
90 Days
|
|
Cost
時間枠:90 Days
|
Cost of hospital stay |
90 Days
|
協力者と研究者
捜査官
捜査官
- スタディチェア:Evangelos J Giamarellos-Bourboulis, MD, Phd、Hellenic Sepsis Study Group
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- REACT
- 2023-507295-40 (EudraCT番号)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。